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A B S T R A C T
Purpose: To review the evidence for efﬁcacy and safety of lacosamide in adult patients with refractory
epilepsy and refractory status epilepticus (RSE).
Methods: A systematic literature search of MEDLINE, PubMed, EMBASE, IPA, Google and Google Scholar
(through October 2014) was performed.
Results: Fourteen studies assessing lacosamide in 3509 refractory epilepsy patients were included. In 3
RCTs, more patients had at least 50% reduction in seizure frequency with lacosamide compared to
placebo with 38.3–41.1%, 38.1–41.2%, and 18.3–25.8%, in the 400 mg/day, 600 mg/day, and placebo
groups, respectively. In non-comparative trials, 18–69% of patients achieved at least 50% reduction in
seizure frequency, and 1.7–26.2% achieved seizure freedom. Non-responders were documented in two
trials, with 26.2–34% having no response. Thirteen studies assessing lacosamide in 390 RSE patients were
included. When assessing lacosamide’s ability to terminate RSE, one comparative cohort study found no
improvement in SE duration or seizure control with addition of lacosamide. Another study documented
no difference compared to use of phenytoin. Eleven descriptive studies using lacosamide as add-on RSE
therapy revealed seizure termination rates of 0–100% (median 64.7%). In all patients receiving
lacosamide, dizziness (21.8%), vision disturbances (10.4%), drowsiness (7.4%), headache (7.0%), nausea
(6.5%), and coordination problems (5.8%) were the most common adverse effects.
Conclusion: Based on evidence to date, adjunctive lacosamide is a treatment option to reduce seizure
frequency in patients with refractory epilepsy and terminate seizures in patients with RSE. The safety
information summary can be used to advise patients of potential adverse effects.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Epilepsy affects up to 2% of the worldwide population, making it
one of the most common neurological disorders.1 Despite the
availability of numerous antiepileptic drugs (AEDs) and the
continuing emergence of novel AEDs, 30% of patients with epilepsy
still suffer from uncontrolled seizures and many experience
unpleasant adverse effects.2* Corresponding author at: Department of Pharmacy, Children’s and Women’s
Health Center of British Columbia, 4480 Oak Street, Vancouver, British Columbia,
Canada V6H 3V4. Tel.: +1 6048752886.
E-mail addresses: vpaquette@cw.bc.ca (V. Paquette), celia.culley@viha.ca
(C. Culley), erica.otto@viha.ca (E.D. Greanya), ensom@mail.ubc.ca (Mary H.H. Ensom).
http://dx.doi.org/10.1016/j.seizure.2014.11.007
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reRefractory epilepsy is deﬁned by the International League
Against Epilepsy (ILAE) as failure of adequate trials of two
tolerated and appropriately chosen and used AED schedules,
whether as monotherapies or in combination, to achieve
sustained seizure freedom.3 Currently, some available therapeu-
tic options to help control refractory epilepsy include adjunctive
sodium-channel blockers (carbamazepine, lamotrigine, phenyto-
in, oxcarbazepine), gamma-aminobutyric acid (GABA) inhibitory
transmission potentiators (valproic acid, topiramate, clobazam,
vigabatrin, phenobarbital), calcium channel modulators/inhibi-
tors (gabapentin, pregabalin, zonisamide, ethosuximide) and
synaptic vesicle protein 2A stimulators (levetiracetam), depend-
ing on the epilepsy syndrome and seizure type.4 Similarly,
refractory status epilepticus (RSE) is deﬁned as failure of ﬁrst
and second-line agents to terminate the seizure, requiring the
addition of a third agent.5 Many of the same therapeutic options,served.
V. Paquette et al. / Seizure 25 (2015) 1–172especially those available in intravenous form, are being
investigated in the treatment of RSE.6
Lacosamide is a new AED believed to exert its anticonvulsant
effects through two novel mechanisms of action. The ﬁrst is
through its enhancement of slow inactivation of voltage gated
sodium channels (VGSC). Depolarization of VGSCs allows sodium
ion inﬂux across neuronal cell membranes, an important step in
the initiation of the action potential. After depolarization, VGSCs
enter an inactivated state before reverting back to their resting
state (where they are available for depolarization again). During
the inactivated state, VGSCs are unavailable for depolarization.
This fast, inactivated state is milliseconds long and is the site of
action of the traditional sodium-channel blockers. In conditions of
sustained depolarization and repetitive ﬁring such as epilepsy,
VGSCs can undergo a conformational change into the slow
inactivation state, which is seconds long. Lacosamide enhances
this transition of VGSCs into the slow inactivated state, reducing
the availability of VGSCs for depolarization and subsequent
neuronal ﬁring.7
The second potential mechanism of action is lacosamide’s
binding to collapsin response mediator protein 2 (CRMP-2), which
is involved in neuronal differentiation, polarization, and axonal
outgrowth.1 To date, the exact effects of the interaction of
lacosamide and CRMP-2 on seizure control have not been
determined, and one study suggests lacosamide does not, in fact,
bind to CRMP-2.8
Lacosamide is available as intravenous (IV) and oral formula-
tions. Lacosamide has 100% bioavailability after oral administra-
tion and exhibits linear (dose-proportional) pharmacokinetics.
Lacosamide’s volume of distribution is approximately 0.6 L/kg and
binding to plasma proteins is <15%. Lacosamide is metabolized by
CYP2C19, CYP2C9, and CYP3A4 into the pharmacologically inactive
O-desmethyl-lasosamide. Ninety-ﬁve percent of the lacosamide
dose is excreted in urine; of this, 40% as unchanged drug, 30% as O-
desmethyl-lacosamide, and the remainder as small amounts of
additional metabolites. Lacosamide has an elimination half-life of
approximately 13 h and appears to have no appreciable pharma-
cokinetic drug interactions.9
Advantages of lacosamide as an AED include its availability as
both oral and IV formulations, excellent bioavailability, minimal
drug interactions, and novel mechanisms of action.
Lacosamide has been available in Europe and the USA since
2008 and in Canada since 2010.9 The purpose of this paper is to
systematically review the available evidence for the efﬁcacy and
safety of lacosamide in adult patients with refractory epilepsy and
RSE.
2. Methods
A search of MEDLINE (1948–October 2014), PubMed (1946–
October 2014), EMBASE (1980–October 2014), IPA (1970–October
2014), Google and Google Scholar was conducted for articles
describing the efﬁcacy and safety of lacosamide in adult patients
with refractory epilepsy or RSE. The following search terms were
used: lacosamide or harkoseride or Vimpat and epilepsy or seizure
or status epilepticus. Reference lists of all identiﬁed articles were
manually searched. Studies were included if patients were >16
years of age and treated with lacosamide for refractory epilepsy or
RSE.
The recent deﬁnition of refractory epilepsy (provided by the
ILAE) and that of RSE suggest patients should have failed at least
two AEDs. In order to ensure all applicable studies were adequately
captured, on initial review we included studies that deﬁned
refractory epilepsy conservatively as failure to respond to one or
more AEDs, provided the population median of failed AEDs prior to
lacosamide introduction was 3 or greater. Studies with thefollowing characteristics were excluded: non-human data, not
published in English, and published as single case reports or
abstract only.
Each study was ranked on the basis of quality of evidence it
provided according to the US Preventive Services Task Force 1996
classiﬁcation system.10 Level I studies are randomized controlled
trials. Level II-1 articles are controlled studies, with patients acting
as their own controls or with a parallel control group included.
Level II-2 articles are deﬁned as cohort or case–control studies.
Level II-3 articles are multiple time series or exceptional
descriptive studies. Level III studies are deﬁned as descriptive
studies and case reports.10
Information extracted included study design, number of
participants, characteristics of the study population, including
previously tried antiepileptic drugs when available, lacosamide
dosing regimens, outcome measures, adverse events and any
information available on therapeutic drug monitoring.
3. Results
For refractory epilepsy, the search produced 20 studies, 14 of
which were included in this review. Three studies were classiﬁed
as level I evidence and the remaining 11 were classiﬁed as level III
evidence. Of the 6 excluded studies, one study was conducted
solely in critically ill patients and was included in the RSE review,
one study included patients only with brain tumor-related
epilepsy, one study did not look at any efﬁcacy outcomes, and 3
studies were single case reports. Results of each study included are
described below and summarized in Table 1.11–24 For RSE, the
search produced 22 studies, 13 of which were included in this
review. No level I evidence was available. Two studies were level II-
2 and the remaining 11 were classiﬁed as level III evidence. All 9
excluded studies were single case reports. Results of each study
included are described below and summarized in Table 2.25–37
3.1. Efﬁcacy of lacosamide in refractory epilepsy
3.1.1. Level I evidence
Three randomized controlled trials (RCTs) have been conducted
assessing the efﬁcacy and safety of lacosamide as adjunctive
treatment in adults with refractory epilepsy. All three trials include
patients with only focal seizures.11–13
In the ﬁrst RCT by Ben-Menachem et al.,11 patients were
randomized to receive oral lacosamide 200 mg/day (100 mg BID),
400 mg/day (200 mg BID), 600 mg/day (300 mg BID) (see Table 1
for titration protocol) or placebo. Patients were eligible if they had
focal seizures for at least 2 years despite previous therapy with at
least 2 other AEDs and had at least 4 seizures per month (with no
seizure-free period longer than 21 days) during an 8-week baseline
phase. If patients experienced adverse events during the titration
phase, dose reduction was allowed once before the patient was
discontinued from the trial. Patients then entered a 12-week
maintenance phase.11
Of the 421 patients randomized, 6 were not included in the
efﬁcacy analysis due to protocol non-compliance and no post-
baseline efﬁcacy assessments.11
The intention-to-treat (ITT) populations for lacosamide
400 mg/day and 600 mg/day demonstrated statistically signiﬁcant
median percent reductions in seizure frequency (compared to the
placebo group) and proportion of patients with at least 50% and
75% reductions in seizure frequency (Table 1). Seven patients
experienced seizure freedom for the entire 12-week maintenance
period (1 in 200 mg/day, 5 in 400 mg/day, and 1 in 600 mg/day
groups). Median change in percentage of seizure-free days (i.e.,
12%) was statistically signiﬁcant in both 400 mg/day and 600 mg/
day groups.11
Table 1
Management of refractory epilepsy.
Trial Design
(LOE)
N Patient
characteristics
Seizure types Other AEDs Lacosamide regimen Outcomes Adverse events,
AE (n)
Therapeutic drug
monitoring
Ben-Menachem
et al. (2007)11
RCT (I) 421 Male 46%
Mean age:
40y (18–68)
Refractory focal
epilepsy
Median monthly
seizure frequency:
11–13
2 concurrent AEDs:
84%
1 concurrent AED:
16%
Failed 7 AEDs:
50%
Initial: 100mg po/day
Titration: 6-week
period increasing by
100mg/day qweek
until 200mg/day,
400mg/day or 600mg/
day
vs. placebo
Maintenance: 12-week
period
415 analyzed for efﬁcacy
Median % reduction in
seizure frequency:
Placebo: 10%
200mg/day: 26% (NSS)
400mg/day: 39%
(p=0.0023)
600mg/day: 40%
(p=0.0084)
50% reduction in seizure
frequency:
Placebo: 21.9%
200mg/day: 32.7% (NSS)
400mg/day: 41.1%
(p=0.0038)
600mg/day: 38.1%
(p=0.0141)
418 analyzed for safety
Any AE:
Lacosamide 270/321 (84%)
Placebo
68/97 (70%)
Most common (10%) in
lacosamide:
Dizziness (112)
Headache (52)
Nausea (46)
Fatigue (45)
Ataxia (42)
Vision abnormal (37)
Vomiting (37)
Diplopia (31)
Somnolence (31)
URTI (31)
Nystagmus (19)
AE highest in 600mg/day group
Discontinuation: 106 (25%)
69 due to AE
Mean plasma
concentrations at
end of maintenance
period:
200mg/day:
4.99mg/mL (n=85)
400mg/day:
9.35mg/mL (n=83)
600mg/day:
12.46mg/mL
(n=61)
Halasz
et al. (2009)12
RCT (I) 485 Male 50%
Mean age:
37.8 y (16–70)
Refractory focal
epilepsy
Failed 4 AEDs:
69%
Failed 7 AEDs:
37%
1 concurrent
AED: 100%
Most common:
CBZ (47.8%)
VPA (32.8%)
LTG (30.5%)
TPM (28.2%)
LEV (19.8%)
Median monthly
seizure frequency:
9.9–11.5
Initial: 100mg po/day
Titration: 4-week
period increasing by
100mg/day qweek
until 200mg/day or
400mg/day
vs. placebo
Maintenance: 12-week
period
Median % reduction in
seizure frequency:
Placebo: 20.5%
200mg/day: 35.3%
(p=0.02)
400mg/day:
36.4% (p=0.03)
Proportion of patients with
50% seizure frequency
reduction:
Placebo: 25.8%
200mg/day: 35% (NSS)
400mg/day: 40.5%
(p=0.01)
AE occurring in 5% of patients
in lacosamide groups:
Dizziness (42)
Headache (31)
Diplopia (29)
Nausea (22)
Vertigo (21)
Fatigue (18)
Nasopharingitis (18)
Abnormal coordination (17)
Vomiting (14)
Discontinuation:
86 (18%)
42 due to AE
Mean plasma
concentrations:
200mg/day:
3.8mcg/mL
400mg/day:
7.4mcg/mL
Chung et al.
(2010)13
RCT (I) 405 Male 49%
Mean age:
38.3 y (16–70)
Refractory focal
epilepsy
82% of patients had
tried 4 AEDs, 48%
who had been
treated with 7
AEDs
All patients on 1
other AED
Most common:
LEV (39%)
LTG (36%)
CBZ (25%)
OXC (21.4%)
PHT (18.9%)
TPM (18.2%)
VPA (16.9%)
ZNM (14.7%)
Median monthly
seizure frequency:
11.5–16.5
Initial: 100mg po/day
Titration: 6-week
period
100mg increments
qweek until 400mg/
day or 600mg/day
vs. placebo
Maintenance: 12-week
period
Median % reduction in
seizure frequency:
Placebo: 20.8%
400mg/day: 37.3%
(p=0.008)
600mg/day: 37.8%
(p=0.006)
Proportion of patients with
50% seizure frequency
reduction:
Placebo: 18.3%
400mg/day: 38.3%
(p<0.001)
600mg/day 41.2%
(p<0.001)
AE occurring in 10% of
patients in lacosamide groups:
Dizziness (135)
Nausea (40)
Diplopia (39)
Blurred vision (38)
Headache (37)
Vomiting (37)
Tremor (33)
Abnormal coordination (29)
Somnolence (27)
Nystagmus (26)
Discontinuation:
89 (22%)
16.5% due to AE
Mean plasma
concentrations:
400mg/day:
7.19mcg/mL
600mg/day:
9.5mcg/mL
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Table 1 (Continued )
Trial Design
(LOE)
N Patient
characteristics
Seizure types Other AEDs Lacosamide regimen Outcomes Adverse events,
AE (n)
Therapeutic drug
monitoring
Wehner
et al. (2009)14
Prospective,
descriptive (III)
25 Male 50%
Mean age:
43y (16–73)
Refractory focal
epilepsy
Mean monthly
seizure frequency:
7 (1–60)
Mean # AEDs: 2 (1–
4)
LTG (13)
LEV (11)
CBZ (6)
ZNM (6)
Mean failed AEDs:
6 (1–14)
Initial: 50mg po BID
Titration: weekly
increments of 50mg
BID to target dose
400mg/day
Follow up: 6 months
50% reduction in seizure
frequency: 32%
90% reduction: 12%
Overall: 13 (52%)
Fatigue (6)
Double vision (5)
Depression (5)
Dizziness (4)
Nausea (3)
Irritability (2)
Word ﬁnding issues (2)
Tremor (2)
Coordination problems (2)
Weight loss (2)
Insomnia (1)
Blurred vision (1)
Memory problems (1)
Itching (1)
Reduced energy (1)
Headache (1)
Reduced performance (1)
Rash (1)
Discontinuation:
7 (28%)
3 due to AE
1 due to death from cancer
Other unknown reason
N/A
Garcia-Morales
et al. (2011)15
Prospective,
descriptive (III)
60 Male 46%
Mean age:
38y (21–69)
Refractory focal
epilepsy
Mean monthly
seizure frequency:
9.7 (2–60)
Mean # concurrent
AEDs: 2.2 (1–4)
LEV (25)
CBZ (19)
LTG (16)
TPM (13)
OXC (13)
Mean failed AEDs:
6.3 (3–13)
Initial: 50mg po daily
Titrated weekly by
50mg/day
Final dose 200–500mg/
day
Follow up: 13–24
months
50% reduction in seizure
frequency: 28 (47%)
Seizure-free: 2 (3.3%)
Overall: 20 (33%)
Dizziness (16)
Diplopia (4)
Somnolence (2)
Increased seizure frequency (2)
Behavioral problems (1)
Pain in ﬁngers and toe nails (1)
Discontinuation 8 (13.3%)
6 due to AE and 2 due to
increase seizure frequency
N/A
Stephen
et al. (2011)16
Prospective,
Descriptive
(III)
113 Male 50%
Median age: 39y
Refractory focal
epilepsy
Median monthly
seizure frequency:
4 (1–120)
Concurrent # AEDs:
1–4 (2 patients on
lacosamide
monotherapy after
d/c of their original
AED)
Median failed
AEDs: 3 (1–12)
Initial: 50mg po daily x
2 weeks
Titration: increased to
50mg po BID then to
target dose of 200–
400mg/day (further
titration unexplained)
65 patients analyzed for
efﬁcacy
Seizure free for 6 months:
26.2%
50% seizure frequency
reduction: 24.6%
Sedation
Ataxia
Dizziness
Agitation
Tremor
Headache
Diplopia
Dysarthria
Nausea
Vomiting (frequency not
deﬁned)
Discontinuation: 14 (12.4%)
10 due to AE, 4 due to lack of
efﬁcacy
N/A
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Husain
et al. (2012)17
Prospective,
Descriptive (III)
Extension of
Chung et al.13
309 Male 52.6%
Mean age: 38.2 y
Refractory focal
epilepsy
Seizure frequency
not reported
Failed 7 AEDs:
50%
All patients on 1–3
other AEDs
Most common
used:
LEV (45.5%)
LTG (38.3%)
CBZ (23.7%)
OXC (23.7%)
TPM (22.7%)
PHT (20.5%)
LZP (19.8%)
VPA (19.2%)
PGB (18.5%)
ZNM (15.9%)
Initial: 200mg po/day
(dose at completion of
Chung et al. study)
Investigators able to
decrease dose to
100mg/day or increase
it to 800mg/day (at
100mg/day weekly
increments)
Median duration: 3
years
9 patients on
lacosamide
monotherapy for 6
months
8 patients on
lacosamide
monotherapy for 12
months
307 patients analyzed for
efﬁcacy
Median percent reduction
in seizure frequency (from
beginning of Chung et al.
study): 48.5%
50% reduction in seizure
frequency: 48.2%
308 patients analyzed for
safety.
Overall: 288 (93.5%)
AE occurring in 10% of
patients:
Dizziness (154)
Headache (67)
Contusion (57)
Nausea (57)
Convulsion (53)
Nasopharyngitis (53)
Fall (49)
Vomiting (49)
Diplopia (47)
Balance disorder (41)
Tremor (41)
URTI (40)
Skin laceration (39)
Depression (36)
Fatigue (36)
Back pain (34)
Nystagmus (34)
Sinusitis (32)
Discontinuation:
170 (55.2%)
33 due to AE
N/A
Verotti
et al. (2012)18
Prospective,
descriptive (III)
59 Male 57.6%
Mean age 215.62
Refractory focal
seizures: 16.9%
Refractory
generalized
seizures: 6.8%
Refractory
secondary
generalized: 13.6%
Refractory mixed:
62.7%
Mean baseline
seizure frequency
per 28 days:
53.1100.37
Concurrent AEDs:
One 6.8%
Two 64.4%
Three 23.7%
Four 5.1%
Speciﬁc AEDs
VPA 30.5%
LEV 18.6%
CBZ 35.6%
CLB 15.2%
TPM 15.2%
LTG 15.2%
Initial: 100mg/day
Titrated: 50mg/day per
week to 100–600mg/
day
Mean ﬁnal dose:
327.3mg/day98.5
Mean follow up
duration: 11.21
months3.59
3 months:
>50% seizure frequency
reduction: 47.4%
Seizure free:
3.4%
6 months:
>50% seizure frequency
reduction: 44.1%
Seizure free: 1.7%
12 months:
>50% seizure frequency
reduction: 39%
Seizure free: 3.4%
Overall: 17 (28.8%)
Dizziness (6)
Headache (4)
Somnolence (3)
Vomiting (2)
Dyspepsia (1)
Nausea (1)
Irritability (1)
Inappetance (2)
Diplopia (2)
Parasthesia (1)
Light headedness (1)
Status epilepticus (1)
Discontinuation: 24 (40.7%)
5 (8.5%) due to AE
N/A
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Table 1 (Continued )
Trial Design
(LOE)
N Patient
characteristics
Seizure types Other AEDs Lacosamide regimen Outcomes Adverse events,
AE (n)
Therapeutic drug
monitoring
Villanueva
et al. (2012)19
Prospective,
descriptive (III)
158 Male 52%
Mean age:
42. 1 y (12–83)
Focal epilepsy
(93.7% refractory)
Mean monthly
seizure frequency:
18.7
Mean concurrent
AEDs: 2.2
Mean failed AEDs:
5.2
Concomitant AEDs:
CBZ
LTG
PHT
OXC
VPA
LEV
TPM
ZNM (frequency
not deﬁned)
Monotherapy: 5
Initial: 50mg po daily
or 100mg BID
Titration:
50mg daily or BID
weekly to a maximum
dose of 400mg/day (if
deemed necessary
doses could be higher,
range 100–800mg/
day)
Follow up: 12 months
Seizure-free at 12 months:
24%
50% reduction in seizure
frequency: 47%
Overall: 49%
Dizziness (40)
Drowsiness (16)
Ataxia (15)
Irritability (11)
Blurred vision (6)
Skin reaction (4)
Headache (3)
Slowness of mental reaction (1)
Diarrhea (1)
Language disturbance (2)
Erectile dysfunction (1)
Hyponatremia (1)
Hypothyroidism (1)
Weight gain (2)
Disorientation (1)
Nausea (1)
Parasomnia (1)
Rhinitis (1)
Mild depression (1)
Discontinuation
48 (30%)
30 due to AE
Remainder due to lack of
efﬁcacy and unspeciﬁed
reasons
N/A
Novy
et al., 201320
Prospective,
descriptive (III)
376 Male 43.6%
Median age:
39.6 (17–76)
Refractory focal
epilepsy 91.2%
Refractory
generalized
epilepsy 3.7%
Unclassiﬁed: 5.1%
Median failed
AEDs: 9 (2–18)
Failed6 AEDs:
87.2%
Concurrent AEDs:
One 16.5%
Two 35.6%
Three 34%
Four 13.8%
Speciﬁc AEDs not
described
Initial:
<50mg/day 0.8%
50mg/day 91%
50–100mg/day 8.2%
Median dose at last
follow up: 400mg/day
(50–650)
Titration not described
Median duration: 1.6 y
5 patients were on
monotherapy after
withdrawal of
concomitant
medications
>50% seizure reduction:
18%
Seizure free>6 months: 3%
>1 year: 1.2%
Overall: 231 (61.4%)
Dizziness (97)
Blurred vision (73)
Drowsiness (51)
Headache (15)
Tiredness (15)
Cognitive complaints (13)
Dysarthria (5)
Insomnia (3)
Nausea (19)
Mood disorders (11)
Irritability (6)
Anxiety (4)
Aggressivity (3)
Allergy (rash or neutropenia)
(7)
Cardiovascular (3)
Other (30)
Discontinuation: 206 (54.8%)
78 (37.9%) due to AE
N/A
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Flores
et al. (2012)21
Retrospective,
descriptive (III)
403 Male 50%
Mean age:
42y (17–82)
Focal epilepsy
92.3%
Generalized
epilepsy
5%
Unclassiﬁed 2.7%
Mean # concurrent
AEDs: 2.29 (0–4)
Initial: 25–200mg/day
Titration not described
Mean max dose:
279.4mg (25–700)
Mean duration: 11.6
months (1 day–42
months)
347 patients included in
analysis.
3 months:
50% reduction in seizure
frequency:
31.1%
Seizure-free: 9.2%
285 patients included in
analysis:
Last 3 months follow up:
50% reduction in seizure
frequency
35.7%
Seizure-free: 9.8%
Overall:
193 (48.7%)
Sedation (89)
Dizziness (73)
Nausea (56)
Unsteadiness (43)
Double vision (42)
Headache (32)
Skin irritation (13)
Weight gain (7)
Mood change (6)
Confusion (6)
Hallucinations (5)
Insomnia (5)
Slurred speech (5)
Numb ﬁngers (4)
Memory problems (4)
Tremor (3)
Abnormal thoughts (3)
Joint pain (3)
Aggression (2)
Breathless (2)
Leg edema (1)
Weakness (1)
Reduced appetite (1)
Myoclonic jerks (1)
Muscle spasm (1)
Drooling (1)
Discontinuation: 150 (38%)
84 due to AE, 35 due to lack of
efﬁcacy, 20 due to increase in
seizure frequency, 11 for
unknown reasons
N/A
Harden
et al. (2012)22
Retrospective,
descriptive (III)
67 Male 48%
Mean age:
38y (18–82)
Refractory epilepsy
Complex partial
(91%)
Generalized tonic–
clonic (36%)
Atonic (16%)
Multiple types:
26 (39%)
Median monthly
seizure frequency:
6
LTG (35)
LEV (25)
BDZ (20)
TPM (18)
ZNM (16)
VPA (14)
OXC (10)
Mean failed AEDs:
8
Mean dose: 278mg/
day (50–600)
Mean duration: 7
months (1–12)
50% reduction in seizure
frequency: 46 (69%)
Seizure-free: 22 (33%)
Dizziness and discoordination
(22)
Psychiatric (10)
Headache (2)
Rash (3)
Dose reductions due to AE (9)
Discontinuation 14 (21%)
5 due to AE, 4 due to lack of
efﬁcacy, and 5 for both
N/A
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Table 1 (Continued )
Trial Design
(LOE)
N Patient
characteristics
Seizure types Other AEDs Lacosamide regimen Outcomes Adverse events,
AE (n)
Therapeutic drug
monitoring
Kamel
et al. (2013)23
Retrospective,
descriptive (III)
128 Male 50%
Mean age:
39 (18–72)
Focal epilepsy 93%
Generalized
epilepsy 7%
Speciﬁc AEDs not
described
Concurrent sodium
channel blockers:
71 (55%)
Initial: 50mg po BID
Titration not described
Final mean dosage:
250mg/day (100–500)
Mean duration: 7
months (1–17)
1 patient on
monotherapy
50% seizure frequency
reduction: 53 (41%)
Seizure-free: 14 (11%)
Overall: 52 (41%)
Dizziness (20%)
Sedation (14%)
Blurred vision (5%)
GI upset (4%)
Headache (3%)
Depression (3%)
Facial swelling (2%)
Weight loss (2%)
Rash (2%)
Discontinuation: 24 (19%)
Not stated exactly how many
were stopped due to AE
N/A
Villanueva
et al. (2013)24
Retrospective,
descriptive (III)
500 Male 53.6%
Mean age (range)
42.4 (18–88)
Focal epilepsy
Mean monthly
baseline seizure
frequency
1124.2
Mean previous
AEDs: 52.9
Concurrent AEDs:
LEV: 49.6%
CLB: 21%
VPA: 21%
ZNM: 16.2%
TPM: 10.4%
CBZ: 36.6%
LTG: 18.2%
OXC: 16.4%
4 titration schedules:
(1) Initial: 100mg/day
div BID
Titration: 100mg/day
per week
(18%)
(2) Initial: 50mg/day
Titration: 50mg/day
per week
(35.4%)
(3) Initial: 50mg/day
Titration: 50mg/day
every 10 days
(12.8%)
(4) Initial: 50mg/day
Titration: 50mg/day
every 2 weeks
(17.6%)
(5) Other (2.4%)
Missing: 13.8%
Mean ﬁnal dose (12
months):
338.5mg96.3
Duration of follow up:
12 months (84.4%)
patients still taking
lacosamide
3 months:
>50% seizure frequency
reduction 44%
Seizure free:
16%
6 months:
>50% seizure frequency
reduction 53%
Seizure free:
15.5%
12 months:
>50% seizure frequency
reduction 57.1%
Seizure free:
14.9%
Overall:
3 months: 29.9%
6 months:
35.4%
12 months:
39.6%
Dizziness (97)
Drowsiness (57)
Blurred vision (32)
Ataxia (31)
Headache (17)
Irritability (12)
GI disturbances (11)
Mental slowness (10)
Skin reaction (6)
Tremor (4)
Parasthesia (2)
Weight loss (1)
Sexual dysfunction (3)
Depression (2)
Leg stiffness (1)
Hallucinations (1)
Other (4)
Discontinuation (by 12
months)
78 (15.6%)
45 (9%) due to AEs
N/A
AED, antiepileptic drug; BDZ, benzodiazepine; CBZ, carbamazepine; CLB, clobazam; GI, gastrointestinal; LEV, levetiracetam; LOE, level of evidence; LZP, lorazepam; LTG, lamotrigine; NSS, not statistically signiﬁcant; OXC,
oxcarbazepine; PGB, pregabalin; PHT, phenytoin; RCT, randomized controlled trial; TPM, topiramate; URTI, upper respiratory tract infection; VPA, valproic acid; ZNM, zonisamide.
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Table 2
Management of refractory status epilepticus.
Trial Design (LOE) N Patient char-
acteristics
Seizure types Other AEDs Lacosamide regimen Outcomes Adverse events,
AE (n)
Therapeutic
drug
monitoring
Sutter et al.
(2013)25
Retrospective
comparative
cohort (II-2)
111 Male 54%
Mean age:
6216y
Focal or absence SE 26%
NCSE 65%
GCSE 9%
BDZ plus
PHT and/or
VPA and/or
LEV
Then IV anesthetic
or other AED after
failure of ﬁrst- and
second-line agents
Mean failed AEDs:
3 0.9 (range 1–5)
200mg IV BID
Dose reductions for
renal dysfunction
One dose escalation to
600mg/day for obesity
(>110kg)
vs.
Any other agents
86 analyzed for comparison
Duration of SE (mean SD)
No LCM:
134.3188.7 h
LCM: 87.2159.4 h
(NSS)
Seizure control
No LCM: 85%
LCM: 93%
(NSS)
Death
No LCM: 39%
LCM: 20%
(OR 0.34, 95% CI 0.1–0.9)
0/111 (0%) N/A
Kellinghaus
et al.
(2014)26
Retrospective
comparative
cohort (II-2)
46 Male 50%
Median age:
68 (18–90) y
Focal SE 41%
NCSE 33%
GCSE 26%
Median interval from
SE onset to therapy:
0.75h (range 0.2–
336h)
BDZ plus LEV 200–800mg IV
(median 400mg) vs.
PHT 750–1500mg
(median 1500mg) vs.
Any other AED
36 analyzed for comparison
of LCM vs. PHT
Seizure termination after
administration:
LCM: 7/21 (33%)
PHT: 6/15 (40%)
(p=0.68)
Time to seizure termination
(median):
LCM: 9.5h (0.5–240h)
PHT: 13.5h (0.5–28.5h)
(p=0.48)
LCM: 0/21 (0%)
PHT: 4/15 (27%)
(p<0.05)
N/A
Miro et al.
(2013)27
Prospective,
descriptive (III)
34 Male 53%
Mean age:
60y (22–86)
FMSE 82.4%
NCSE 14.7%
GCSE 2.8%
Median interval from
SE onset to therapy:
4.5h (range 0.3–240h)
BDZ plus
PHT and/or
VPA and/or
LEV
Failed 4 AEDs:
76.5%
100–400mg IV bolus
(at median of 48h
(range 1–250h) after SE
therapy initiated)
100mg IV (2.9%)
200mg IV (20.6%)
300mg IV
(26.5%)
400mg IV (50%)
Maintenance: 100–
600mg po or IV/day
(mean 323.53mg)
(LCM used as a 4th or
later option in 76.5% of
patients)
Seizure termination with
no further AED
change48h: 64.7%
2/34 (5.9%)
Diplopia (1)
Confusion/Nystagmus
(1)
AE resolved with dose
reduction
Discontinuation:
0
N/A
Legros et al.
(2014)28
Prospective,
descriptive (III)
25 Male 52% RSE 84%
SC 16%
Mix of convulsive, non-
convulsive,
generalized, partial
Number of AEDs
failed (median 3;
range 1–5)
BDZ then
PHT and/or
VPA and/or
LEV
Then IV anesthetic
or other AED
200mg IV over 15min
vs.
400mg IV over 15min
Subsequent dose
200mg po q12h
Seizure cessation after
administration:
Overall: 36% (9/25)
200mg: 18.2% (2/11)
400mg: 50% (7/14)
(p=0.2)
Seizure termination within
3h:
200mg: 0% (0/11)
400mg: 28.6% (4/14)
(p=0.023)
5/25 (20%)
Myoclonus/confusion
(1)
Increased seizure
severity (1)
Dizziness (1)
Ataxia (1)
Increased ALT (1)
Discontinuation:
0
N/A
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Table 2 (Continued )
Trial Design (LOE) N Patient char-
acteristics
Seizure types Other AEDs Lacosamide regimen Outcomes Adverse events,
AE (n)
Therapeutic
drug
monitoring
Albers et al.
(2011)29
Retrospective,
descriptive (III)
7 Male 86%
Age range:
33–83y
Focal 71% GCSE 29% Prior BDZ, LEV, PHT,
VPA, TPM,
anesthetic
Order of IV LCM
2nd: 14%
4th: 29%
5th: 57%
Loading dose 400mg IV
Maintenance 400mg/d
IV
Seizure cessation within
24h with no additional
AEDs required:
100%
Not reported N/A
Goodwin et al.
(2011)30
Retrospective,
descriptive (III)
9 Male 22%
Age range:
47–89y
NCSE 67%
GCSE 33%
Median interval from
SE onset to LCM
therapy: 2d (range 0–
14d)
Failure of 2 AEDs or
more
(median 3; range
2–5)
Other AED: BDZ,
PHT, LEV PB
Loading dose
100–300mg IV
Maintenance dose
100–200mg IV BID
(max 200mg IV q8h)
Seizure cessationwithin 4h
or absence of EEG seizure
activity for 24h following
emergence from burst
suppression:
0/9 (0%)
2/9 (22%)
Acute angioedema (2)
Discontinuation: 1/9
(11%)
N/A
Ho¨ﬂer
et al.
(2011)31
Retrospective,
descriptive (III)
31 Male 55%
Median age:
67y (22–95)
FMSE 32%
NCSE 32%
GCSE 36%
BDZ or PHT or VPA
or LEV or anesthetic
Order of IV LCM
1st: 6.5%
2nd: 19.4%
3rd: 48.4%
4th: 25.8%
200–400mg IV
(median 200mg) at
max rate 60mg/min
Subsequent dose 0–
400mg IV (median
200mg)
SE cessation after
administration:
80.6% (25/31)
Order of IV LCM
1st: 100% (2/2)
2nd: 100% (6/6)
3rd: 73% (11/15)
4th: 75% (6/8)
48 analyzed for safety:
2/48 (4.2%)
Pruritis and skin rash
(2)
Discontinuation: 1/48
(2.1%)
N/A
Kellinghaus
et al.
(2011)32
Retrospective,
descriptive (III)
39 Male 46%
Mean age:
63y (18–90)
Focal 85%
GCSE 15%
Median interval from
SE onset to therapy:
0.75h (range 0.1–
336h)
1st line BDZ: 95%
Prior
LEV: 85%
PHT: 36%
Other AED: 13%
Anesthetic: 10%
Order of IV LCM
1st: 3%
2nd: 10%
3rd: 49%
4th or greater: 38%
200–400mg IV bolus
over5min
SE cessation after
administration:
44% (17/39)
Order of IV LCM
1st or 2nd: 60% (3/5)
3rd: 57% (11/19)
4th or greater: 20% (3/15)
1/39 (2.6%)
Allergic skin reaction
(1)
Discontinuation: 0
N/A
Koubeissi
et al.
(2011)33
Retrospective,
descriptive (III)
4 Male 0%
Age range:
53–79y
NCSE 100%
Interval from SE onset
to LCM therapy: range
3–50h
Failure of BDZ and
one or more of PHT,
LEV and pregabalin
Order of IV LCM
3rd: 50%
5th: 50%
Loading dose
50–100mg IV
Maintenance 100–
200mg IV BID
Seizure cessation:
100%
Time from LCM
administration to seizure
cessation:
15min–2h
0/4 (0%) N/A
Rantsch
et al.
(2011)34
Retrospective,
descriptive (III)
10 episodes
in 9 patients
Male 33%
Mean age:
67.112.4 y
NCSE 80%
Focal 20%
Median interval from
SE onset to LCM
therapy: 166h (range
8–637h)
Lacosamide 4th
line or greater
(median 6.5, range
4–12)
Loading dose 50–
100mg IV
Maintenance dose
50mg IV BID
Seizure cessation after
administration:
2/10 (20%)
0/10 (0%) N/A
Cherry
et al.
(2012)35
Retrospective,
descriptive (III)
13 episodes
in 10 patients
Male 38%
Mean age:
51.1 y (24–
80)
FMSE 33%
NCSE 48%
GCSE 7.5%
Myoclonic 7.5%
Failure of 2 AEDs
(mean 2.8; range 1–
7)
BDZ, LEV, PHT, VPA,
PB, other AED,
anesthetic
Loading dose
Mean 178mg (50–
400mg) at mean
3.1mg/min (range 1.7–
6.7mg/min)
Maintenance dose
Mean 326mg/d (100–
400mg/d)
Seizure cessation after
administration:
38% (5/13)
Time to seizure cessation:
11.2h (range 1.5–21h)
>50% reduction in seizure:
54% (7/13)
6/13 (46%)
Hypotension (5)
Elevated transaminases
(>2baseline) (1)
Discontinuation: 1/13
(8%)
N/A
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V. Paquette et al. / Seizure 25 (2015) 1–17 11Patients in the lacosamide 400 mg/day group experienced the
most improvement in quality of life with a Quality of Life in
Epilepsy (QOLIE-31) score improvement of 2.7 points compared to
an overall score of 1.3 points in the placebo group. A greater
proportion of patients showed improvement with the Clinical
Global Impression of Change (CGIC) score in the 200 mg/day (35%),
400 mg/day (40%), and 600 mg/day (38%) groups compared to
placebo (25%).11
Dose proportionality was seen for plasma concentrations of
lacosamide and none of the concomitant AED plasma concentra-
tions were affected by lacosamide.11
The second RCT, by Halasz et al.,12 randomized patients to
receive lacosamide 200 mg/day (100 mg po BID), 400 mg/day
(200 mg po BID) or placebo. Inclusion criteria and study protocol
were identical to those of Ben-Menachem et al.11 with the only
difference being a 4-week, rather than 6-week titration phase.12
Of the 485 patients randomized, 477 were included in the ITT
analysis; 8 patients did not have any post-baseline efﬁcacy
assessment. Statistically signiﬁcant median percent reductions
in seizure frequency over placebo were seen in both 200 mg/day
and 400 mg/day groups whereas proportion of patients with at
least 50% seizure frequency reduction was signiﬁcantly higher only
in the 400 mg/day group (Table 1). Eleven patients were seizure
free throughout the 12-week maintenance phase (5 in 200 mg/day,
3 in 400 mg/day, and 3 in placebo groups). Patients receiving
400 mg/day had signiﬁcantly more seizure-free days (5%) over
placebo.12
No change in plasma concentrations of any of the other AEDs
were found when administered concomitantly with lacosamide.12
In the most recent RCT, by Chung et al.,13 patients were
randomized to receive lacosamide 400 mg/day (200 mg po BID),
600 mg/day (300 mg po BID) or placebo.13 Inclusion criteria and
study protocol were identical to those of Ben-Menachem et al.11
(Table 1).
Of the 405 randomized patients who received at least one dose
of lacosamide, 402 had at least one post-baseline efﬁcacy
assessment and were included in the ITT analysis.13
Signiﬁcant differences were found for both 400 mg/day and
600 mg/day groups compared with placebo in median percent
reductions in seizure frequency per month from baseline and
proportion of patients with at least 50% and 75% reductions in
seizure frequency (Table 1).13
There was evidence for dose-related seizure reduction in
patients who experienced secondary generalized seizures
(n = 176). In placebo (n = 45), lacosamide 400 mg/day (n = 84),
and 600 mg/day (n = 47) groups, 50% responder rate was 33.3%,
56% and 70%, respectively. The median percent seizure reduction
was 14.3%, 59.4% and 93% in the placebo, lacosamide 400 mg/day,
and 600 mg/day groups, respectively. Dose-related seizure
reduction was seen in patients with complex partial seizures
(n = 331), but not in those with simple partial seizures (n = 149).
For the latter patients, those receiving placebo experienced the
greatest median percent seizure reduction and had the greatest
proportion of patients with at least 50% reduction in seizure
frequency.13
Nine patients were seizure-free throughout the 12-week
maintenance period (4 in 400 mg/day and 5 in 600 mg/day
groups). Both groups had greater proportion of seizure-free days
compared to placebo; (5.3%, p = 0.013) for 400 mg/day and (8.2%,
p < 0.001) for 600 mg/day.13
Dose proportionality was seen with lacosamide plasma
concentrations. Plasma concentrations of other AEDs were not
affected by lacosamide except for one patient who had low valproic
acid (VPA) levels in the 600 mg/day lacosamide group. Lacosamide
was unlikely to be the cause of this as no other patients who were
receiving VPA experienced this effect.13
V. Paquette et al. / Seizure 25 (2015) 1–17123.1.2. Level of evidence III
3.1.2.1. Prospective non-comparative studies. Seven prospective
descriptive studies evaluated the efﬁcacy and safety of lacosamide
in adult patients with refractory epilepsy who had focal
seizures.14–20 Only one study included patients with both focal
and generalized seizures.18
In the ﬁrst study, by Wehner et al.,14 25 patients with refractory
focal epilepsy were followed for 6 months after initiation of oral
lacosamide as adjunctive treatment. In addition to the other
concomitant AEDs, 3 patients had prior epilepsy surgery, 6 had
undergone vagus nerve stimulator placement, 2 were scheduled to
undergo respective epilepsy surgery and 2 had been offered the
surgery but declined. Twenty patients (80%) were taking lacosa-
mide in addition to another sodium-channel blocker AED.14
During the 6-month follow up, 3 patients had periods of seizure
freedom lasting 1, 4, and 5 months. Of the 8 patients with at least
50% reduction in seizure frequency (Table 1), 6 were on another
sodium-channel blocker AED in addition to lacosamide. One
patient receiving pregabalin and lamotrigine substituted the
lamotrigine with lacosamide and experienced a 100% increase in
seizure frequency.14
In a study by Garcia-Morales et al.,15 60 patients treated with
oral adjunctive lacosamide for refractory focal seizures were
assessed for efﬁcacy and safety for 13–24 months. Overall, a 50%
response rate was seen in 28 patients (47%), with 11/17 patients
(65%) in the nocturnal seizure group and 17/43 patients (40%) in
the daytime seizure group (Table 1). Difference between these two
groups was not statistically different, although the study was not
powered to show this.15
In patients taking lacosamide with other sodium-channel
blockers, the 50% response rate was seen in 18/40 (45%) vs.
15/20 (75%) in patients taking lacosamide in combination with
non-sodium-channel blocking AEDs.15
In a prospective descriptive audit by Stephen et al.,16 113
patients with refractory focal epilepsy received oral lacosamide
200–400 mg/day. Doses were titrated until one of the following
endpoints: seizure freedom for 6 months, at least 50% reduction
in seizure frequency (responder), <50% reduction in seizure
frequency for 6 months on highest tolerated lacosamide dose
(marginal responder) or lacosamide withdrawal because of side
effects, lack of efﬁcacy or both. Sixty-ﬁve patients reached an
endpoint, but no other data were provided for the remaining 48
(Table 1).16
Patients were more likely to stay seizure free when lacosamide
was the ﬁrst add-on AED (15/36, 41.7%) compared to later in the
treatment schedule (1/27, 3.7%, p = 0.001). Seizure freedom was
just as likely to occur in patients taking other sodium-channel
blockers (5/26, 19.2%) as those taking other AEDs with different
mechanisms of action (11/37, 29.7%). Complete seizure freedom
was achieved in one patient on lacosamide monotherapy at a dose
of 200 mg/day after VPA had been withdrawn due to signs of
neurotoxicity. Overall, of the 65 patients whose data were
available, 78% had beneﬁt with the addition of lacosamide16
(see also Table 1).
A prospective descriptive study, by Husain et al.,17 is an open-
label extension of the RCT by Chung et al.13 Patients from that RCT
were asked if they would like to participate in the extension and, if
they agreed, were placed on oral lacosamide 200 mg/day at the
conclusion of the RCT. During this study, lacosamide dosages could
be decreased to 100 mg/day or increased up to 800 mg/day
maximum. Concomitant AEDs could also be dose-adjusted or
added or discontinued. The duration of follow up ranged from 3 to
5 years.17
Nine patients (8 who experienced a median percent reduction
in monthly seizure frequency ranging from 53.6% to 100%) weremaintained on lacosamide monotherapy for >6 months and 8
patients (7 who sustained at least 50% reductions in seizure
frequency over the entire treatment period) for >12 months.17 (see
also Table 1.)
A prospective descriptive study, by Verotti et al.,18 evaluated
efﬁcacy and safety of adjunctive lacosamide in 118 adult (16
years of age) and pediatric patients (<16 years of age) with
refractory epilepsy (focal and generalized seizures). Only results
for the adults (n = 59) are described here. Patients had to have a
one-year history of epileptic seizures despite treatment with at
least two other AEDs. They had to have at least 2 seizures per 28
days on average prior to enrollment.18
By the end of the 12-month follow-up period, 2 (3.4%) patients
remained seizure-free, 23 (39%) remained responders (at least a
50% seizure frequency reduction), and 10 (16.9%) remained non-
responders. No statistically signiﬁcant differences between groups
by seizure type were found. An increase in seizure frequency was
seen in 3 (5%) patients at 3 months, 2 (3.4%) at 6 months and no
patients experienced an increase in seizure frequency at 12 months
follow up.18
In a prospective, multicenter descriptive study by Villanueva
et al.,19 158 patients with focal seizures were started on
lacosamide therapy and followed for 12 months. All patients
had tried at least one AED prior to this study; however, 5 patients
were not receiving any therapy at enrollment.19
At 12 months, nearly a quarter of patients were seizure-free and
nearly half were responders, deﬁned as at least a 50% reduction in
seizure frequency (Table 1). Three- and 6-month seizure free rates
were 22.8% and 15.8%, respectively; 3- and 6-month responder
rates were 44.3% and 46.2%, respectively. There were fewer
seizure-free patients who were already on a sodium-channel
blocker compared to those on concomitant AEDs with different
mechanisms of action (34.7% vs. 17.3%, p = 0.017) as well as fewer
responders (65.3% vs. 37.5%, p = 0.001). However, neither seizure-
free nor responder rates differed among different epilepsy types or
etiologies (data not presented).19
Novy et al.,20 in the most recent prospective observational
study, evaluated efﬁcacy and safety of lacosamide treatment in 376
adult patients with refractory epilepsy who were treated for a
median duration of 1.6 years. Thirty-seven percent of patients had
some period of seizure improvement or seizure freedom (Table 1).
Seven percent of patients experienced worsening of seizures. There
was no signiﬁcant difference in any efﬁcacy outcomes between
people with focal and generalized seizures. Primary reason for
lacosamide discontinuation was lack of efﬁcacy (127/206
patients).20
3.1.2.2. Retrospective non-comparative studies. Four retrospective
descriptive studies have assessed efﬁcacy and safety of lacosamide
in adult epileptic patients.21–24 Three studies included patients
with both focal and generalized seizure types.21–23
In the ﬁrst retrospective descriptive study, by Flores et al.,21 403
patients with focal or generalized epilepsy treated with lacosamide
and had at least one follow-up clinic visit were retrospectively
reviewed for efﬁcacy and safety of lacosamide, with all outcomes
compared to a 3-month baseline.21
Of 403 patients reviewed, 347 achieved the minimum 3 months
follow up and were included in the analysis. At 3 months, 108
patients (31.1%) had at least 50% reduction in seizure frequency, 98
(28.2%) had <50% reduction in seizure frequency, 50 (14.4%) had
increase in seizures, and 91 (26.2%) were unchanged.21
In the last 3 months of follow up, 285 patients were included in
the analysis. Of these patients, 102 (35.7%) had at least 50%
reduction in seizure frequency, 62 (21.7%) had seizure frequency
reduction of <50%, 53 (18.6%) had increase in seizure frequency
and 68 patients (23.8%) were unchanged.21
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partial, and simple partial), highest seizure reduction and
seizure-free rates were seen in patients with tonic–clonic
seizures.21
In a subgroup analysis at one of the study centers, outcomes in
116 patients who were involved in ﬁnal follow-up analysis were
compared between patients taking lacosamide plus another
sodium-channel blocking agent vs. other AEDs with different
mechanisms of action. Most patients (92.2%) had focal seizures.
There was no difference between the two groups regarding 50%
reduction in seizure frequency or being seizure-free.21
In the second retrospective study, Harden et al.22 reviewed 67
patients with refractory epilepsy treated with lacosamide. Forty-
six of 67 patients (69%) achieved the primary efﬁcacy outcome of at
least 50% reduction in seizure frequency. Mean daily dose of these
responders was 293 mg compared to 243 mg in patients who did
not respond. Twenty-two patients, including two patients receiv-
ing lacosamide monotherapy, had no seizures in the most recent
treatment month. Fifty-three patients took concurrent sodium-
channel blocking AEDs; 34 were responders (64%) vs. 12 of the 14
patients (86%) not taking concurrent sodium-channel blocking
AEDs (p > 0.05).22
Kamel et al.,23 conducted a retrospective review of 128 patients
who received lacosamide for treatment of focal or generalized
seizures (Table 1). Average time patients were seizure free on
lacosamide was 35 weeks. Forty-four patients (34%) had no
response; no patients had seizure worsening. There was no
signiﬁcant difference in reduction of seizure frequency between
the higher lacosamide doses (>200 mg/day) compared to lower
lacosamide doses (<200 mg/day). Nor was there signiﬁcant
difference in the subgroup of patients taking concurrent sodi-
um-channel blocking agents in terms of 50% responders. However,
this study was not powered to a detect difference in either
outcome.23
In the most recent, and largest, retrospective descriptive study,
by Villanueva et al.,24 efﬁcacy and safety of lacosamide was
investigated over a one-year period in 500 patients with focal
epilepsy and classiﬁed into early add-on treatment group
(previously failed 1 or 2 AEDs prior to starting lacosamide:
20.4%) and late add-on treatment group (previously failed at least 3
AEDs prior to starting lacosamide: 79.6%).24
At least 50% reduction in seizure frequency occurred in 74.7% of
the early add-on group compared to 52.6% of the late add-on group
(p < 0.001). Seizure freedom occurred in 41.4% of the early vs. 8.1%
of the late add-on groups (p < 0.001) (Table 1).24
Patients not taking concomitant sodium-channel blockers had
higher seizure-free rates compared to those receiving concomitant
sodium-channel blocking AEDs at all evaluation timepoints, 3
months (22.8% vs. 13.5%; p = 0.014), 6 months (24.1% vs. 12.3%;
p = 0.001) and 12 months (27.1% vs. 12.3%; p < 0.001). No speciﬁc
combinations of adjunctive lacosamide with other AEDs were
found to be associated with responder or seizure-free rates.24
3.2. Efﬁcacy of lacosamide in refractory status epilepticus (RSE)
3.2.1. Level of evidence II-2
3.2.1.1. Retrospective comparative cohort. In a study by Sutter
et al.,25 all adult patients diagnosed with RSE from January 2005 to
December 2011 in a single center, who had not previously received
IV lacosamide were identiﬁed. The standardized protocol is
presented in Table 2. In 2009, IV lacosamide became available
and was used as one of the non-sedating third-line agents; or, at
the neurologist’s discretion, lacosamide could have been used as
the second agent.25Of 111 patients with RSE, 29 had focal motor or absence SE, 10
had generalized convulsive SE (GCSE), and 72 had non-convulsive
SE (NCSE). Twenty-ﬁve patients with SE caused by hypoxic–
ischemic encephalopathy were excluded due to overall poor
outcomes associated with this seizure type, leaving 86 patients in
the comparative cohort. Forty-ﬁve of these patients were treated
with IV lacosamide. Lacosamide was the ﬁnal AED administered to
51% of patients. Seven percent received lacosamide concurrently
with a second-line AED. While duration of SE and seizure control
numerically favored lacosamide treatment, these did not reach
statistical signiﬁcance. Mortality signiﬁcantly improved with
lacosamide therapy when adjusted for age (OR 0.34, 95% CI 0.1–
0.9), but no signiﬁcant differences were seen in discharge
destination.25
In a retrospective cohort study by Kellinghaus et al.,26 all adult
patients diagnosed with RSE from August 2008 to December 2010
in a single center, were identiﬁed. Forty-six patients with varying
seizure types who had failed ﬁrst-line benzodiazepine and a
second-line AED (levetiracetam in 85% of patients) were included.
Patients given phenytoin (median 1500 mg IV) or lacosamide
(median 400 mg IV) as third-line agent (36/46, 78%) were
analyzed.26
Of the 36 patients compared, 15 patients received phenytoin
and 21 lacosamide, with mean time from seizure onset to
administration of third agent of 14.5 and 19 h, respectively. No
signiﬁcant differences were found between the groups in overall
seizure termination rates or time to seizure termination (see
Table 2).26
3.2.2. Level of evidence III
3.2.2.1. Prospective non-comparative studies. In a prospective case
series by Miro et al.,27 34 patients diagnosed with RSE (28 focal
motor SE, 5 NCSE and one GCSE) who had received IV lacosamide
following use of a standard protocol (see Table 2) were identiﬁed
prospectively from 6 Spanish hospitals.27
Efﬁcacy, deﬁned as cessation of seizures with no change in AED
for at least 48 h after clinical or electrographic seizure resolution,
was achieved in 64.7% of patients, the majority of SE ceasing within
12 h of the ﬁrst lacosamide dose (Table 2). Further AED or
anesthetic therapy was required in 12 patients.27
In the second prospective case series by Legros et al.,28 25
patients diagnosed with RSE (n = 21) or seizure cluster (n = 4) who
had received IV lacosamide following failure of at least 3 other
AEDs either acutely or chronically were identiﬁed prospectively
from a Belgian medical need program.28
Lacosamide 200 mg IV bolus was initially used from October
2010 to June 2011, and due to poor initial results, lacosamide
400 mg IV bolus was subsequently used per protocol from July
2011 to December 2012. Response, deﬁned as lacosamide being
the last AED added before seizure termination, was achieved in 36%
of patients, with no statistically signiﬁcant difference in response
between the two dosages. Early seizure termination within 3 h of
lacosamide administration was signiﬁcantly greater in the 400 mg
dose group (Table 2).28
3.2.2.2. Retrospective non-comparative case series. Nine retrospec-
tive case series have assessed efﬁcacy and safety of lacosamide in
adults with RSE.29–37 The case series, consisting of 4–55 patients,
encompassed a range of seizure types including refractory focal,
non-convulsive, and generalized convulsive SE.
In all cases, benzodiazepine and multiple AEDs were used in an
attempt to terminate seizure activity, with lacosamide added in as
ﬁrst- to ﬁfth-line or greater (median, third-line or greater). Loading
doses ranged from 50 to 400 mg IV and were followed by
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seizure cessation after administration of lacosamide, was 0–100%.
The largest retrospective study, Garces et al., reviewed 55
patients with RSE within a total population of 98 that included 43
patients with acute repetitive seizures or seizure clusters.37 Only
results of RSE patients are presented. The majority of patients
received lacosamide as the third (or more) AED. Thirty-nine of 55
patients (70.9%) achieved the primary efﬁcacy outcome of seizure
cessation after lacosamide administration. In multivariate analysis,
no single factor [i.e., order of lacosamide administration (ﬁrst-/
second-line vs. third-line or later), time to administration,
concurrent sodium-channel blocker, seizure type, and lacosamide
dose (200 mg vs. >200 mg)] signiﬁcantly inﬂuence response;
however, bivariate analysis indicated shorter time to lacosamide
administration and NCSE seizure type were associated with
signiﬁcantly greater chance of response.37
Kellinghaus et al.32 reviewed 39 patients with focal or
generalized RSE treated with an IV lacosamide bolus, with the
majority of patients receiving it as the third or greater AED.
Seventeen of 39 patients (44%) achieved the primary efﬁcacy
outcome of seizure cessation after lacosamide administration.
Rates of efﬁcacy were higher in those who received lacosamide
earlier in the sequence, with approximately 60% of patients
responding when lacosamide was given as third-line treatment or
earlier, and 20% when given as fourth-line or greater.32
Ho¨ﬂer et al.31 reviewed 31 patients with refractory focal, NCSE,
or convulsive SE given IV lacosamide. One patient received
lacosamide as ﬁrst-line agent, with all others failing benzodiaze-
pines or other AEDs, and lacosamide given as the third or fourth
agent. Seizures were terminated in 81% of patients, with similar
efﬁcacy regardless of when lacosamide was given in relation to
other AEDs.31
The remaining 6 retrospective case series each included 4–10
patients.29,30,33–36 Lowest efﬁcacy rates were seen by Goodwin
et al.,30 where 0 of 9 patients responded to IV lacosamide within a
4-h timeframe from administration or remained seizure free for
24 h following emergence from burst suppression sedation. Using
low-dose lacosamide bolus of 50–100 mg IV demonstrated an
efﬁcacy rate of seizure termination of 100% in 4 patients with
refractory NCSE within 2 h,33 to 20% in 10 episodes of primarily
non-convulsive RSE.34
3.3. Safety and tolerability of lacosamide in adult patients
Side effects and discontinuation rates for each study are listed
in Tables 1 and 2. Total number of patients who received
lacosamide in this review was 3899, although frequency of
adverse events was not reported in every study.
The more commonly reported adverse events included dizziness
(826/3899, 21.2%), diplopia/blurred vision (394, 10.1%), drowsiness/
sedation/somnolence (283, 7.3%), headache (265, 6.8%), nausea (247,
6.3%), ataxia/balance/coordination problems (221, 5.7%), vomiting
(139, 3.6%), fatigue (120, 3.1%), tremor (83, 2.1%), nystagmus (80,
2.1%), upper respiratory tract infection (URTI) (71, 1.8%), nasophar-
yngitis (71, 1.8%), contusion (58, 1.5%), falls (49, 1.3%), depression (48,
1.2%), skin laceration (39, 1.0%), and back pain (34, 0.9%).
Eighty-eight patients (2.3%) experienced worsening of seizures
on lacosamide (Flores et al. = 53, Novy et al. = 26, Verotti = 5, Garcia-
Morales et al. = 2, Wehner et al. = 1, Legros et al. = 1)14,15,18,20,21,28
indicating that lacosamide may not be suitable for every patient.
Unfortunately, at this time, we cannot predict which patients will
experience this outcome.
A few studies reported on rate of adverse events in patients
taking lacosamide with other concurrent sodium-channel blocking
AEDs compared to those taking lacosamide with AEDs with
different mechanisms of action. In Wehner et al.,14 69% of patientswho experienced side effects were on lacosamide plus another
sodium-channel blocker,. In Garcia-Morales et al.,15 >50% of
patients who reported dizziness were also on other sodium-
channel blockers. In Villaneuva et al.,19 32.7% of patients not taking
other sodium-channel blockers experienced an adverse event
compared to 57.7% of patients on concurrent sodium-channel
blocking AEDs (p = 0.004). In Harden et al. and Novy et al.,20,22
there was no difference in side effects between patients on
concurrent sodium-channel blockers and those not. In Novy
et al.,20 however, for 41 patients (19%) experiencing central
nervous system adverse events, reducing other sodium-channel
blocking AEDs (phenytoin, lamotrigine, carbamazepine or oxcar-
bazepine) signiﬁcantly improved or resolved symptoms. Kamel
et al.23 saw more adverse events in patients on concurrent sodium-
channel blockers compared with those on AEDs with other
mechanisms of action (51% vs. 28%, p = 0.01). Lastly, Villanueva
et al.24 showed more adverse events in patients receiving
concurrent sodium-channel blockers compared to patients on
non-sodium-channel blockers (42.5% vs. 31.9%, p = 0.029). Flores
et al.,21 reported no difference in adverse events or withdrawals
between patients on concurrent sodium-channel blockers and
those not.
Other rare, but sometimes serious, adverse events were
observed in some trials. In Ben-Mehachem et al.,11 electrocardio-
grams (ECGs) revealed no prolongation of QT interval, but a small
increase in PR interval (4.2 ms for the 400 mg/day dose) and ﬁrst-
degree AV block occurred in 3 patients (no lacosamide discontin-
uation for these adverse events). In Halasz et al.,12 2 patients in the
400 mg/day lacosamide group experienced a psychotic disorder.
ECGs showed no QT prolongation but a small increase in PR
interval of 4.6 ms in patients on 400 mg/day. In Chung et al.,13 ECG
showed no effect on QT interval but a small increase in PR interval
of 4.4 ms and 6.1 ms for patients in the 400 mg/day and 600 mg/
day lacosamide treatment groups, respectively. In Garces et al.,37 2
patients, both with underlying ischemic cardiomyopathy, demon-
strated ECG changes. One had asymptomatic PR interval prolonga-
tion after a 200 mg infusion, with resolution upon dose reduction.
The other had third-degree AV block after 400 mg IV (total) was
administered with concurrent beta blocker. Lacosamide was
withdrawn in this patient until a permanent pacemaker was
implanted. In Wehner et al.,14 2 patients both on lacosamide
400 mg/day lost >10% of their body weight. In Husain et al.17
serious adverse events considered related to trial medication
included atrial ﬁbrillation and ventricular extra systoles (2
patients). There were also two reports of suicidal ideation (no
other information was given). In the RSE case series by Goodwin
et al.,30 two of 9 patients had acute angioedema thought to be
related to IV administration of lacosamide; one required discon-
tinuation of lacosamide.
Discontinuation rates in the refractory epilepsy trials ranged
from 12.4%16 to 55.2%17 The most common reason for discontinu-
ation in 7 studies was adverse events.11,15,16,19,21,22,24 Discontinu-
ation was rare in the RSE trials.
4. Discussion
To the best of our knowledge, this systematic review is the ﬁrst
to evaluate clinical efﬁcacy and safety of lacosamide for refractory
seizures (including focal and generalized epilepsy) and refractory
status epilepticus in adults, using all published evidence (including
post-marketing data).
Currently, lacosamide is approved for use in adult patients for
adjunctive treatment of refractory focal seizures. In the US only,
lacosamide is also approved for monotherapy in adult patients
with focal seizures.9 In the 3 RCTs,11–13 lacosamide demonstrated
efﬁcacy over placebo for median percent seizure reduction ranging
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600 mg/day,11,12 and for proportion of patients with at least 50%
reduction in seizure frequency ranging from 33% to 41% of patients
at doses of 400 mg/day11–13 and 600 mg/day.11,12
While RCTs sit atop the hierarchy of evidence and are
important for establishing efﬁcacy and safety, these phase II/III
trials do not always accurately reﬂect efﬁcacy and tolerability of
new medications in the routine clinical setting due to their short
durations and strict exclusion criteria. Altogether, 11 post-
marketing descriptive studies in refractory epilepsy14–24 revealed
a response rate of at least 50% reduction in seizure frequency in
18–69% of patients. Although not every study reported seizure
freedom, this important outcome was achieved in 3–33% of
patients.11,16,19–23
None of the post-marketing observational studies explicitly
evaluate or discuss the issue of tolerance; however, ﬁve of these
studies17,24 did evaluate efﬁcacy at different time points during the
follow-up period. Husain et al.,17 had the longest follow-up period
of ﬁve years. There was no decline in median percent reduction in
seizure frequency or proportion of 50% responders over the follow-
up period; however, this was evaluated based on patients
remaining in the study. Novy et al.,20 had the second longest
follow-up period of up to three years with 51 (14%) patients
retaining 50% seizure frequency reduction at end of follow up.
Verotti et al.,18 and both studies by Villanueva et al.,19,24 had
follow-up periods of 12 months with efﬁcacy evaluations
occurring at three, six and 12 months. While Verotti et al.,18
showed a mild decrease in 50% responders over the 12-month
period, one study by Villanueva et al.,19 showed no difference in
response rate and the other study by Villanueva et al.,24 saw an
increase in the proportion of patients with a 50% decrease in
seizure frequency over the 12 months. While tolerance does not
seem to occur with lacosamide use, more studies with longer
follow-up periods evaluating this are required.
Currently, lacosamide is not approved for treatment of
generalized epilepsy.9 While Harden et al.,22 reported that
lacosamide could be an effective treatment option in generalized
epilepsy, speciﬁcally atonic seizures, most patients had focal
seizures and 26 of 67 patients had multiple seizure types. Although
Flores et al.21 saw higher seizure reduction and seizure freedom in
patients with tonic–clonic seizures, this study included only 20
with generalized epilepsy, out of a total of 403 patients. While
Novy et al.20 included 3.7% of patients with generalized seizures,
no speciﬁc information was available on efﬁcacy of lacosamide in
this subpopulation. Verotti et al.18 included 4 patients with
generalized seizures, one of whom had complete seizure resolution
at 3, 6 and 12 months; however, the remaining 3 patients
experienced either no response or seizure worsening. Due to
limited evidence in a very small number of patients, no
recommendations can be made at this time.
Lacosamide is not currently approved for use in SE and no RCTs
are available in this population. Animal models suggested that
early treatment with lacosamide signiﬁcantly and dose-depen-
dently reduced SE seizure activity.25 These initial ﬁndings, in
addition to the availability of an IV formulation, the apparent lack
of signiﬁcant cardiac or respiratory effects associated with IV
infusion, and minimal drug interactions make lacosamide an
attractive agent for ongoing study in SE. Of the available studies in
this population, one comparative cohort study documented no
signiﬁcant improvement in duration of SE or seizure control with
addition of lacosamide in RSE patients,26 and another showed no
difference in efﬁcacy compared with phenytoin for seizure
termination and time to seizure termination.27 Eleven post-
marketing descriptive studies using lacosamide as add-on therapy
in RSE revealed seizure termination rates of 0–100% (median
64.7%).28–38 These studies included varied seizure types of SE(focal, generalized–convulsive, non-convulsive and myoclonic).
Due to the small numbers of patients, varying seizure types and
wide range of effectiveness reported, the role of IV lacosamide for
RSE treatment remains unknown. The small numbers of adverse
events reported in these RSE trials, however, may make it an
attractive option in these patients who fail standard therapy.
All of the refractory epilepsy studies evaluated lacosamide as
adjunctive therapy; however, a few studies included some patients
on lacosamide monotherapy. Husain et al.17 included 8 patients
receiving lacosamide monotherapy for at least 12 months and 7 of
them sustained at least 50% reductions in seizure frequency over
the entire treatment period. Although Villanueva et al.,19 Kamel
et al.,23 Harden et al.22 and Novy et al.20 had small numbers of
patients receiving lacosamide monotherapy (n = 13), these studies
did not speciﬁcally report patient outcomes. A larger historical
controlled trial published by Wechsler et al. evaluating the use of
lacosamide monotherapy in patients with focal seizures showed
efﬁcacy of lacosamide monotherapy at doses of 400 mg per day.39
Lacosamide is now approved for monotherapy use in adults with
focal epilepsy but still remains only approved for use as adjunctive
treatment in Canada and Europe.
Several refractory epilepsy studies also evaluated efﬁcacy of
lacosamide, a novel sodium-channel blocker, in combination with
other sodium-channel blockers compared to lacosamide in
combination with AEDs with different mechanisms of action.
While Garcia-Morales et al.15 showed that more patients receiving
lacosamide in combination with AEDs with different mechanisms
of action had at least 50% reduction in seizure frequency compared
to lacosamide in combination with other sodium-channel blockers,
3 other studies21–23 showed no difference between the two groups.
Villanueva et al.24 found a higher seizure-free rate in patients
receiving AEDs of different mechanisms of action in addition to
lacosamide compared to the other sodium-channel blockers while
Stephen et al.16 found seizure freedom just as likely in either group.
Unfortunately, at this time, there is insufﬁcient and conﬂicting
information to be able to recommend speciﬁc AED combinations
with lacosamide.
The most commonly reported adverse events of lacosamide in
adults were dizziness, vision disturbances, headache, nausea,
balance and coordination problems, drowsiness, sedation, somno-
lence, vomiting, fatigue, tremor, nystagmus, URTI, nasopharyngitis,
contusion, falls, depression, skin laceration, and back pain. Adverse
events were similar between all 14 refractory epilepsy studies,
with dizziness being predominant and a primary reason for
lacosamide discontinuation. Few adverse events were reported
with IV lacosamide for RSE, and three patients of 264 studied
required discontinuation of lacosamide.
A few published case reports describe possible lacosamide-
associated cardiac events such as sinus node dysfunction, atrial
ﬁbrillation/ﬂutter and ventricular tachycardia.40–42 In the 3
RCTs11–13 and one extension study,17 monitoring for possible
cardiac adverse events was conducted and PR interval prolonga-
tions were noted in all 4 studies. Although there were no serious
clinical implications and none of the other observational studies
noted any cardiac-related adverse events, pharmacovigilance and
reporting of cardiac abnormalities is still required as more patients
use this new agent.
As in analysis of efﬁcacy, several studies also investigated
whether there were differences in adverse events between
patients taking lacosamide with other sodium-channel blockers
compared to patients on concomitant AEDs with different
mechanisms of action. Of the 8 studies14,15,19–24 that assessed
this outcome, 514,15,19,23,24 saw more adverse events in patients
taking more than one sodium-channel blocker. While conﬂicting
results exist within a small number of patients and no robust
recommendations can be made about speciﬁc combination
V. Paquette et al. / Seizure 25 (2015) 1–1716therapy with lacosamide, it is reasonable to consider the potential
for additive side effects among medications with similar adverse
event proﬁles when selecting combinations of AEDs.
Only the 3 RCTs11–13 collected plasma concentrations of
lacosamide. All 3 showed a relationship between lacosamide dose
and concentration. While no information was given on t
relationship between lacosamide concentration and efﬁcacy or
safety, based on lacosamide’s linear dose–concentration response,
therapeutic drug monitoring is likely of little value.
Some study limitations need to be addressed. The 3 RCTs11–13
were phase II/III clinical trials for approval of lacosamide, had strict
exclusion criteria, and were conducted for short periods (12
weeks). This has implications in terms of occurrence of adverse
events given that some adverse events take time to manifest and
may be less likely to occur in healthier patients. Also, in all 3
RCTs,11–13 there was a titration phase and patients were
discontinued from the trial if they required a second-dose
alteration due to adverse events. This procedure removes patients
from the trial who were most likely to experience adverse events of
lacosamide. Of note, for all trials included in this review, the
majority of adverse events were patient- or caregiver-reported.
This introduces recall bias and possibly inaccurate reporting. The
retrospective nature of some studies adds the element of possible
underreporting and erroneous recording of adverse events in the
medical record.
All of the non-comparative studies share some similar
limitations in that they were observational by design with no
comparator and had small sample sizes. Hence, some studies were
not designed to detect improved clinical outcomes compared to
clinical practice prior to the availability of lacosamide. Also,
although the number of patients included in each study was based
on those who received at least one dose of lacosamide, many
patients were omitted from efﬁcacy and safety analysis due to lack
of tolerability during the titration periods or lack of adequate
follow up. Removing such patients may skew results, potentially
making lacosamide seem less efﬁcacious than it may be, or seem
better tolerated than it may be.
Most of the included studies relied on patient and caregiver
reports of seizure frequency by means of a seizure diary. Not only
does this introduce recall bias but also seizures must be clinically
noticeable in order to be recorded, and depending on the type of
seizure, this may not always be the case.
Despite the aforementioned limitations, all studies included in
this review, with the exception of a single RSE study,30 showed
varying degrees of beneﬁt, with minimal adverse effects, when
adding lacosamide to therapy of focal refractory seizures and RSE
in adult patients. In patients with difﬁcult-to-treat epilepsy
experiencing multiple seizures per day, reduction in seizure
frequency will most likely improve their quality of life, although
this outcome was only speciﬁcally tested by Ben-Menachem
et al.,11 in which patients receiving 400 mg/day lacosamide scored
better on the QOLIE 31 scale compared to placebo. That, coupled
with other advantages including no known clinically relevant drug
interactions and availability of an IV formulation, make lacosamide
an attractive option in these setting.
5. Conclusion
This systematic review of the literature assessing use of
lacosamide in adult patients revealed 14 studies including a total
of 3509 patients with refractory epilepsy and 13 studies including
a total of 390 patients with RSE. Based on this evidence,
lacosamide, used in combination with other AEDs, was well
tolerated and reduced seizure frequency by at least 50% in 18–69%
of patients with refractory focal seizures, and was effective in
terminating seizures in patients with RSE. Dosing for treatment ofrefractory epilepsy appears to be patient-speciﬁc but can be
initiated at 100 mg/day divided twice daily and titrated over a
period of 4–6 weeks to maximal doses of 600–800 mg/day divided
twice daily. An adequate trial of lacosamide appears to be 12
weeks. Loading doses of 50–400 mg IV can be used to treat RSE.
Ongoing pharmacovigilance is required for monitoring of adverse
events.
Conﬂict of interest statement
None declared.
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